CIK 0001061983 · Large accelerated filer
CYTOKINETICS INC
Sign in to watch- Ticker
- CYTK
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- operating
- EIN
- 943291317
- Phone
- (650) 624-3000
- Business address
- 350 OYSTER POINT BOULEVARD, ., SOUTH SAN FRANCISCO, CA, 94080
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $12,208,275
- in 16 filings, $12.2M under 10b5-1 plans
Net −$12,208,275. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-03-02 | Callos Andrew EVP, Chief Commercial Officer | Option exercise · Incentive Stock Option (Right to Buy) 10b5-1 | −886 | 0 | ||
| 2026-02-05 | Callos Andrew EVP, Chief Commercial Officer | Option exercise 10b5-1 | +15,000 | $23.26 | $349K | 65,440 |
| 2026-02-05 | Callos Andrew EVP, Chief Commercial Officer | Sale 10b5-1 | −15,000 | $61.93 | $929K | 50,440 |
| 2026-02-05 | Callos Andrew EVP, Chief Commercial Officer | Option exercise · Non-Qualified Stock Option (Right to Buy) 10b5-1 | −15,000 | 84,000 | ||
| 2026-02-02 | Callos Andrew EVP, Chief Commercial Officer | Option exercise 10b5-1 | +886 | $37.63 | $33K | 51,326 |
| 2026-02-02 | Callos Andrew EVP, Chief Commercial Officer | Sale 10b5-1 | −886 | $62.10 | $55K | 50,440 |
| 2026-02-02 | Callos Andrew EVP, Chief Commercial Officer | Option exercise · Incentive Stock Option (Right to Buy) 10b5-1 | −886 | 886 | ||
| 2026-01-15 | Daly James M Director | Grant or award | +197 | $63.44 | $12K | 197 |
| 2026-01-15 | Wysenski Nancy Director | Grant or award | +98 | $63.44 | $6K | 30,971 |
| 2026-01-15 | WIERENGA WENDELL Director | Grant or award | +98 | $63.44 | $6K | 32,542 |
| 2026-01-15 | Kaye Edward M. MD Director | Grant or award | +197 | $63.44 | $12K | 10,174 |
| 2026-01-15 | HENDERSON JOHN T Director | Grant or award | +334 | $63.44 | $21K | 74,912 |
| 2026-01-15 | Harrington Robert Arthur Director | Grant or award | +197 | $63.44 | $12K | 18,739 |
| 2026-01-05 | Callos Andrew EVP, Chief Commercial Officer | Option exercise 10b5-1 | +15,000 | $23.26 | $349K | 65,440 |
| 2026-01-05 | Callos Andrew EVP, Chief Commercial Officer | Sale 10b5-1 | −15,000 | $60.28 | $904K | 50,440 |
| 2026-01-05 | Callos Andrew EVP, Chief Commercial Officer | Option exercise · Non-Qualified Stock Option (Right to Buy) 10b5-1 | −15,000 | 99,000 | ||
| 2026-01-02 | Callos Andrew EVP, Chief Commercial Officer | Sale 10b5-1 | −913 | $62.09 | $57K | 50,440 |
| 2026-01-02 | Callos Andrew EVP, Chief Commercial Officer | Option exercise 10b5-1 | +885 | $37.63 | $33K | 51,325 |
| 2026-01-02 | Callos Andrew EVP, Chief Commercial Officer | Sale 10b5-1 | −885 | $63.16 | $56K | 50,440 |
| 2026-01-02 | Callos Andrew EVP, Chief Commercial Officer | Option exercise · Incentive Stock Option (Right to Buy) 10b5-1 | −885 | 1,772 |
Page 12 of 22 · 429 trades